The company said that the Centers for Medicare and Medicaid Services wrongly suspended its Medicare reimbursement payments, causing financial distress.
The company also reported higher operating costs as it worked to develop and validate its Parsortix circulating tumor cell collection system for clinical use.
Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
The deal covers Curetis' Unyvero A50 instrument system and test cartridges, and builds on a separate distribution agreement the company recently signed.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
The clearance marks the first time that the tests have been indicated to follow a new paradigm in which two enzyme immunoassay tests can be conducted concurrently or sequentially, the FDA said.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
With the firm seeing lower profitability in diagnostics, its CEO said it is focusing on improving earnings strength with the Atellica Solution IVD platform.
LabCorp Diagnostics was down 2.8 percent, while Covance Drug Development was up 8 percent. The firm narrowed its revenue and earnings guidance for the year.
